Get the Stockscreener App
44.43
2.59%
-1.18
After Hours:
44.43
Agios Pharmaceuticals Inc stock is traded at $44.43, with a volume of 808.52K.
It is down -2.59% in the last 24 hours and down -3.22% over the past month.
Agios Pharmaceuticals Inc is a biopharmaceutical company with a focus on developing treatments geared towards cancer and rare genetic disorders of metabolism. The company's primary focus is to develop potentially transformative small-molecule medicines. The clinical development plan for Agios' product candidates includes a precision approach with initial study designs that allow for genetically or biomarker-defined patient populations. The company seeks the potential for proof of concept early in clinical development, along with any potential for accelerated approval.
See More
Previous Close:
$45.61
Open:
$45.61
24h Volume:
808.52K
Relative Volume:
1.61
Market Cap:
$2.53B
Revenue:
$29.40M
Net Income/Loss:
$-352.62M
P/E Ratio:
-11.25
EPS:
-3.95
Net Cash Flow:
$-318.99M
1W Performance:
-2.91%
1M Performance:
-3.22%
6M Performance:
+51.95%
1Y Performance:
+79.52%
1-Day Range:
$44.16
$46.24
1-Week Range:
$41.97
$53.28
52-Week Range:
$19.80
$53.28
Agios Pharmaceuticals Inc Stock (AGIO) Company Profile
Name
Agios Pharmaceuticals Inc
Sector
Industry
Phone
617-649-8600
Address
88 SIDNEY STREET, CAMBRIDGE, MA
Agios Pharmaceuticals Inc Stock (AGIO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-08-24 | Initiated | Cantor Fitzgerald | Overweight |
| Feb-03-23 | Initiated | Piper Sandler | Overweight |
| Nov-17-22 | Upgrade | Goldman | Sell → Neutral |
| Jul-27-22 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Dec-03-21 | Initiated | BofA Securities | Buy |
| Jul-30-21 | Downgrade | Goldman | Neutral → Sell |
| Jul-01-21 | Initiated | Raymond James | Mkt Perform |
| Jun-10-21 | Initiated | H.C. Wainwright | Buy |
| Mar-01-21 | Downgrade | JP Morgan | Overweight → Neutral |
| Mar-01-21 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Feb-26-21 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Oct-22-20 | Upgrade | Barclays | Equal Weight → Overweight |
| Mar-04-20 | Initiated | Barclays | Equal Weight |
| Nov-26-19 | Initiated | Cantor Fitzgerald | Overweight |
| Sep-23-19 | Upgrade | Guggenheim | Neutral → Buy |
| May-23-19 | Resumed | Goldman | Neutral |
| Feb-15-19 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Sep-25-18 | Initiated | Leerink Partners | Mkt Perform |
| May-23-18 | Initiated | Citigroup | Buy |
| Apr-11-18 | Reiterated | Credit Suisse | Outperform |
| Feb-15-18 | Reiterated | Needham | Buy |
| Feb-15-18 | Reiterated | SunTrust | Buy |
| Sep-15-17 | Initiated | RBC Capital Mkts | Outperform |
| Aug-10-17 | Reiterated | Needham | Buy |
| Aug-08-17 | Reiterated | SunTrust | Buy |
| Aug-02-17 | Upgrade | Leerink Partners | Mkt Perform → Outperform |
| Jun-26-17 | Downgrade | Janney | Buy → Neutral |
| Jan-17-17 | Upgrade | Oppenheimer | Perform → Outperform |
| Oct-24-16 | Initiated | Needham | Buy |
| Jun-13-16 | Upgrade | JP Morgan | Neutral → Overweight |
| May-18-16 | Reiterated | SunTrust | Buy |
View All
Agios Pharmaceuticals Inc Stock (AGIO) Latest News
Agios Pharmaceuticals CFO sells shares worth $124,634 - Investing.com
D. E. Shaw & Co. Inc. Buys 316,100 Shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) - MarketBeat
Agios Pharmaceuticals (NASDAQ:AGIO) Downgraded by Leerink Partnrs - MarketBeat
Where are the Opportunities in (AGIO) - Stock Traders Daily
Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Shares Sold by Axa S.A. - MarketBeat
Wall Street SWOT: Agios stock navigates turbulent waters in genetic disease market - Investing.com India
Wall Street SWOT: Agios stock navigates turbulent waters in genetic disease market - Investing.com Canada
Agios Pharmaceuticals (NASDAQ:AGIO) Shares Gap Down to $48.05 - MarketBeat
Agios cut at Leerink on overhang from Pfizer’s Oxbryta withdrawal - MSN
Wall Street SWOT: Agios stock navigates turbulent waters in genetic disease market - Investing.com UK
Do Options Traders Know Something About Agios (AGIO) Stock We Don't? - Yahoo Finance
Agios cut at Leerink on overhang from Pfizer’s Oxbryta withdrawal - Seeking Alpha
Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
Agios Pharmaceuticals (NASDAQ:AGIO) Lowered to Market Perform at Leerink Partners - MarketBeat
Pfizer Pulls Key Sickle Cell Drug Over Safety Concerns - Finimize
Agios stock hits 52-week high at $51.25 amid robust growth - Investing.com Canada
Piper Sandler maintains Overweight rating on Agios Pharma stock By Investing.com - Investing.com Canada
Agios stock hits 52-week high at $51.25 amid robust growth - Investing.com
Pfizer Tanked A $5.4 Billion Takeover. Why Crispr, Agios, Beam Could Benefit. - MSN
Agios Pharmaceuticals (NASDAQ:AGIO) Sets New 1-Year High at $53.50 - MarketBeat
We're Not Very Worried About Agios Pharmaceuticals' (NASDAQ:AGIO) Cash Burn Rate - Simply Wall St
American Century Companies Inc. Increases Stake in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) - MarketBeat
Beta Thalassemia Pipeline 2024: Clinical Trials Assessment, - openPR
Biliary Tract Cancer Pipeline Analysis 2024: FDA Approvals - openPR
Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Shares Sold by Profund Advisors LLC - MarketBeat
Farallon Capital Management LLC Acquires 63,900 Shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) - MarketBeat
Stocks of Agios Pharmaceuticals Inc (AGIO) are poised to climb above their peers - SETE News
Acadian Asset Management LLC Makes New Investment in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) - Defense World
Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Shares Sold by State of New Jersey Common Pension Fund D - MarketBeat
Agios Pharmaceuticals (NASDAQ:AGIO) Earns Overweight Rating from Cantor Fitzgerald - MarketBeat
Edgestream Partners L.P. Purchases Shares of 42,076 Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) - MarketBeat
Seven Eight Capital LP Acquires New Stake in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) - MarketBeat
Seven Eight Capital LP Makes New Investment in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) - Defense World
Agilon Health Inc [AGL] CEO & President makes an insider purchase of 20,000 shares worth 67188.0. - Knox Daily
Agios Pharmaceuticals (NASDAQ:AGIO) Rating Reiterated by Royal Bank of Canada - MarketBeat
Agios Pharmaceuticals (NASDAQ:AGIO) Rating Reiterated by Royal Bank of Canada - Defense World
Victory Capital Management Inc. Has $2 Million Stake in Agilysys, Inc. (NASDAQ:AGYS) - Defense World
Bike fashion brand AGU saved from collapse - Ruetir
If EPS Growth Is Important To You, Agilysys (NASDAQ:AGYS) Presents An Opportunity - Simply Wall St
Trading Day Triumph: Agilon Health Inc (AGL) Ends at 3.28, a -7.08 Surge/Plunge - The Dwinnex
Agios Pharmaceuticals (AGIO) Appreciated after Positive Testing Results - Yahoo Finance
Agilon Health Inc (AGL) Stock: A Year of Highs and Lows in the Market - The InvestChronicle
Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Short Interest Down 16.2% in August - MarketBeat
Breaking down AGL’s current quarter earnings estimates - US Post News
Arizona State Retirement System Cuts Position in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) - Defense World
Companies Like Agios Pharmaceuticals (NASDAQ:AGIO) Are In A Position To Invest In Growth - Yahoo Finance
FDA Grants Orphan Drug Tag to AGIO's Tebapivat for Rare Cancer - MSN
Headlands Technologies LLC Makes New Investment in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) - MarketBeat
Balance Sheet Dive: Agilon Health Inc (AGL)’s Debt-to-Equity and Long-Term Debt/Eq Ratios - The Dwinnex
Drug developers index falls as cancer trials hit setbacks - BioWorld Online
FDA Grants Orphan Drug Tag to AGIO's Tebapivat for Rare Cancer - Yahoo Finance
Agios Pharmaceuticals Inc Stock (AGIO) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.05%
4.86%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):